Short Interest in Interpace Biosciences, Inc. (OTCMKTS:IDXG) Expands By 7,750.0%

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 785 shares, a growth of 7,750.0% from the May 31st total of 10 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 11,418 shares, the short-interest ratio is presently 0.1 days.

Interpace Biosciences Price Performance

Shares of IDXG opened at $1.65 on Friday. Interpace Biosciences has a 1 year low of $0.70 and a 1 year high of $2.40. The business has a 50-day moving average of $1.82 and a 200-day moving average of $1.69. The company has a market capitalization of $7.31 million, a price-to-earnings ratio of -33.00 and a beta of 0.59.

Interpace Biosciences (OTCMKTS:IDXG) last posted its quarterly earnings results on Tuesday, May 12th. The business services provider reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $9.03 million for the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.